ArticleFrontiers in neurology2024
Diagnostic potential of blood-based biomarkers in multiple sclerosis.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigating the Relationship Between Visual Evoked Potentials, Neurological and Neuropsychological Status in Primary Progressive Multiple Sclerosis.Journal of clinical medicine · 2026Article
- Cathepsins in Neurological Diseases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS). There is a significant delay in diagnosing MS as the symptoms and tests overlap with other diseases. Blood-based biomarkers, which quantify fragments of proteins involved in MS pathophysiology, have the potential as diagnostic biomarkers. In this study, we evaluated biomarkers by immunoassays, of tissue destruction, reflected by biglycan degraded by matrix metalloproteinases (MMPs) (BGM), cathepsin S-degraded nidogen (NIC), and MMP-degraded secreted protein acidic and rich in cysteine (SPARC-M) in healthy donors and patients diagnosed with MS. The biomarkers were able to separate the two groups with an AUC = 0.710, AUC = 0.765, and AUC = 0.875, respectively. These pathologically released protein fragments could potentially be used as biomarkers in clinical management providing a specific protein fingerprint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.